LCTX Stock Analysis: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.10
-0.03 (-2.65%)
▼
5d:
+1.85%
30d:
-14.73%
90d:
-19.71%
HOLD
MODERATE Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.10, which is considered slightly low relative to its 30-day fair value range of $1.07 to $1.28.
Technical Outlook: Technically, LCTX is in a strong downtrend. Immediate support is located at $1.00, while resistance sits at $1.18.
Market Sentiment: The stock shows a mixed technical setup (48/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.50 (+386.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LCTX is in a strong downtrend. Immediate support is located at $1.00, while resistance sits at $1.18.
Market Sentiment: The stock shows a mixed technical setup (48/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.50 (+386.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.07 -
$1.28
Company Quality Score
59/100
(HOLD)
Options IV Signal
26th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 26th percentile)
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 386.7% below Wall St target ($5.50)
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$1.07 -
$1.28
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.17
(15.5%)
Support & Resistance Levels
Support Level
$1.00
Resistance Level
$1.18
Current Trend
Strong Downtrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.56
Wall Street Target
$5.50
(+386.7%)
Revenue Growth (YoY)
14.8%
Share & Embed Analysis
Last updated: August 08, 2026 7:03 PM ET
Data refreshes hourly during market hours. Next update: 8:03 PM
Data refreshes hourly during market hours. Next update: 8:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian M Culley
BUY
15000 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 47 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 64 BUY |
